The ANTICOV clinical trial responds to the urgent need to identify treatments that can be used to treat mild and moderate cases of COVID-19 early and prevent spikes in hospitalizations that could overwhelm fragile and already overburdened health systems in Africa.

 

Launched in September 2020, ANTICOV aims to enrol up to 3,000 participants. The trial will be carried out at 19 sites in 13 countries by the ANTICOV consortium, which includes 26 prominent African and global research and development organizations, coordinated by the Drugs for Neglected Diseases initiative (DNDi).

Clinical trial tracker

AVAREF and ANTICOV: Accelerating regulatory approval for COVID-19 treatments in Africa

How do you obtain the approval to quickly launch a clinical trial in 13 African countries while ensuring that the most stringent ethical standards are respected? Watch this video to find out.

Partners

Funding

Major funding for the ANTICOV consortium is provided by the German Federal Ministry of Education and Research (BMBF) through KfW and by the global health agency Unitaid as part of ACT-A. Early support to launch the initiative was provided by the European & Developing Countries Clinical Trials Partnership (EDCTP), under its second programme supported by the European Union with additional funding from the Swedish government, and the Starr International Foundation, Switzerland.

  • European and Developing Countries Clinical Trials Partnership (EDCTP2), Europe 
  • Federal Ministry of Education and Research (BMBF) through KfW, Germany 
  • Médecins Sans Frontières International 
  • Starr International Foundation, Switzerland 
  • Stavros Niarchos Foundation (SNF) 
  • Swiss Agency for Development and Cooperation (SDC), Switzerland 
  • The ELMA Foundation 
  • UK aid, UK 
  • Unitaid, Switzerland